Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Evercore ISI Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lifted by analysts at Evercore ISI from $750.00 to $875.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Evercore ISI’s target price indicates a potential upside of 16.12% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. UBS Group raised their target price on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 price objective for the company. Scotiabank increased their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Finally, Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $794.70.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $753.55 on Thursday. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market cap of $79.20 billion, a price-to-earnings ratio of 18.04, a price-to-earnings-growth ratio of 1.97 and a beta of 0.39. The business has a fifty day moving average of $755.38 and a two-hundred day moving average of $643.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the previous year, the firm earned $12.46 EPS. The business’s revenue was up .9% on a year-over-year basis. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 8,431 shares of company stock valued at $5,733,521 over the last quarter. 7.02% of the stock is owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in REGN. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at $226,000. CX Institutional boosted its stake in Regeneron Pharmaceuticals by 7.9% in the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 22 shares in the last quarter. Sowell Financial Services LLC grew its holdings in shares of Regeneron Pharmaceuticals by 4.7% during the second quarter. Sowell Financial Services LLC now owns 583 shares of the biopharmaceutical company’s stock worth $306,000 after purchasing an additional 26 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 10.9% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 459 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 45 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha previews Regeneron’s Q4 and expects an earnings beat and a strong 2026, maintaining a Buy rating and noting the shares have rallied >16% since the author’s prior note — this supports upside if results meet or exceed guidance. Read More.
• Positive Sentiment: Zacks says Regeneron has the right setup to beat upcoming earnings (Earnings “ESP”/estimates upside), which could trigger further upside if the company reports above-consensus results. Read More.
• Positive Sentiment: Evercore ISI raised its price target on REGN from $750 to $875 and kept an “outperform” call — a material analyst upgrade that increases implied upside and can support buying interest. Read More.
• Positive Sentiment: MarketBeat aggregation (reported on DefenseWorld/American Banking News) shows an average analyst rating of “Moderate Buy” across ~28 brokerages, indicating broad analyst conviction that could limit downside absent a negative print. Read More.
• Neutral Sentiment: Reminders that Regeneron will release quarterly earnings on Friday — serves as the immediate event risk/reward driver; expect heightened volume and larger intraday moves around the report. Read More.
• Neutral Sentiment: Zacks compares REGN with Illumina (ILMN) on valuation — useful context for investors weighing sector alternatives, but not an immediate catalyst for REGN alone. Read More.
• Neutral Sentiment: A Zacks piece highlights two medical names that could beat earnings (including REGN), which reinforces market attention on earnings-season upside but is not new company-specific data. Read More.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.